AUPH
Aurinia Pharmaceuticals Inc
16.70$
+0.4%
vs. previous close
Closing price · As of: Sep 22, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -35.9% | +69.8% | +233.1% | -23.2% | +122.3% | +43.0% | +17.2% | -13.3% | +16.4% | +0.5% | +36.5% | |
| – | -50.7% | +150.5% | +323.1% | -24.2% | +137.2% | +33.1% | +22.4% | -13.8% | -4.0% | +5.1% | +10.2% | |
| – | -74.6% | +588.8% | +317.7% | -28.8% | +159.4% | -11.0% | -14.9% | -59.4% | -48.1% | +70.7% | -3.9% | |
| – | -51.8% | +151.7% | +337.5% | -27.4% | +143.2% | +30.2% | +17.0% | -16.5% | -10.0% | +2.3% | +11.0% | |
| – | -48.9% | +83.0% | +26.7% | +99.1% | +69.6% | -86.1% | +30,123.5% | -12.5% | +78.7% | +51.7% | +13.4% | |
| – | – | – | -10,900,100.0% | – | – | – | +38.8% | +28.1% | +60.4% | -1.2% | +16.5% | |
| – | -30.8% | -19.4% | +6.9% | +32.3% | +126.8% | +5,046.2% | +104.8% | -12.7% | – | – | – | |
| – | -8.1% | -8.5% | -9.2% | -10.6% | -29.8% | +5.3% | -9.9% | -23.5% | -22.5% | -12.5% | -13.6% | |
| – | +87.1% | +54.7% | +14.5% | +38.1% | -22.8% | +117.5% | +15.0% | +1.8% | +160.0% | +1.8% | -1.7% | |
| – | +27.5% | +119.2% | +2.8% | -10.9% | +55.6% | +183.3% | +27.0% | +13.4% | +67.4% | +26.7% | -4.1% | |
| – | – | – | +38.9% | -97.1% | +5,752.5% | -88.6% | +34.4% | -11.6% | +1,566.5% | -3.4% | +16.7% | |
| – | +49.4% | +37.7% | +31.8% | +87.4% | -41.3% | -36.6% | +47.2% | -20.4% | +40.2% | +19.9% | -36.1% | |
| – | -51.1% | +66.2% | +29.1% | – | – | – | – | – | – | – | – | |
| – | -55.7% | +80.1% | +361.0% | -32.1% | +165.2% | +36.6% | +17.5% | -15.4% | -6.8% | -0.1% | +54.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +10.3% | +9.7% | +118.1% | +10.2% | +9.7% | +27.4% | +9.2% | +9.7% | +0.9% | +2.1% | -5.1% |
Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.